NCT05738980View on ClinicalTrials.gov

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

NARecruitingINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

Autologous RAK cells

Autologous RAK cells were treated by intravenous reinfusion

Trial Locations (1)

100730

RECRUITING

Beijing Hospital Center of Biotherapy, Beijing

All Listed Sponsors
lead

Beijing Hospital

OTHER_GOV